Deals Shaping The Medical Industry, February 2018

 
• By Beth Allan, Deanna Kamienski, and Maureen Riordan

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.

Dealmaking

HTG Molecular Diagnostics Inc. netted $37.9mm through a public offering of 13.9mm common shares (including the overallotment) at $2.90. The company markets instruments, services and reagents for molecular profiling applications, including the HTG EdgeSeq gene expression profiling system. (Jan.)

Investment Banks/Advisors: Cantor Fitzgerald & Co.; HC Wainwright & Co

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo